AstraZeneca PLC (AZN) Stock Score, Valuation & Financial Research
AstraZeneca PLC is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for AZN
AstraZeneca PLC currently has a Wall Street Score of 35/100. The stored market price is $160.17. Its financial score is 25/100. Its valuation score is 43/100. The latest WSS change is +0.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What AstraZeneca PLC does
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partne
AZN financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $160.17
- Market capitalization:
- $248.40B
- Revenue:
- $61.37B
- Net income:
- $10.45B
- Free cash flow:
- $8.67B
- Cash:
- $4.89B
- Total debt:
- $32.20B
- EPS:
- 6.72
- P/E ratio:
- 23.8x
- Financial score:
- 25/100
- Valuation score:
- 43/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $8.67B, showing positive cash generation.
- The balance sheet shows $4.89B of cash versus $32.20B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.6 points: AZN increased 0.6 points because Valuation improved by 2.3 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 43/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research AZN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.